A practical reference on Lyophilisation: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-03-16 and is reviewed periodically as new material appears.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Modified synthetic peptide | 39-residue backbone with non-natural residues |
| Receptor targets | GIP and GLP-1 | Dual incretin receptor agonist |
| Approximate molecular mass | 4,813 Da | Calculated from the peptide sequence |
| Administration route | Subcutaneous injection | Weekly schedule in approved products |
| Albumin binding | Present | Mediated by a C20 fatty diacid side chain |
Solid tirzepatide is handled as a lyophilised, hygroscopic peptide powder that should be kept desiccated, protected from light, and stored frozen, typically at or below minus twenty degrees Celsius for long-term retention. Material left at ambient temperature for extended periods can take up moisture, which promotes aggregation and deamidation. Commercial liquid presentations are kept refrigerated between two and eight degrees Celsius and are not frozen. Reconstituted laboratory solutions are generally held cold and used within a short window because hydrolysis and oxidation continue slowly in solution.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography for the main peak and with mass spectrometry for the observed molecular mass. Peptide mapping after enzymatic digestion confirms the primary sequence, while amino acid analysis provides a quantitative composition check. Size-exclusion chromatography and ion-exchange chromatography are used to look for aggregates and charge variants. Water content, residual solvents, and counter-ion content are measured separately, since a lyophilised powder is often reported on an as-is basis unless a correction is applied.
Research-grade material circulates through suppliers that differ widely in documentation and testing practice, so a certificate of analysis is a starting point rather than proof of quality. Independent verification typically repeats chromatographic purity and mass confirmation on the received lot, and compares results against a retained reference standard. Regulatory status varies by jurisdiction, and a substance cleared as a medicine is not interchangeable with a research chemical of the same name. Open questions include how closely non-pharmaceutical lots match approved material in impurity profile and in aggregate content.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
==== Hypertension ==== A possible treatment for hypertension is blocking peripheral vascular seretonergic neurons or alpha-adrenergic neurons on postsynaptic cell sites. One study showed that benzoctamine, a serotonin and alpha-adrenergic antagonist, does not reduce blood pressure through a seretonin mechanism but does reduce blood pressure by antagonizing alpha-adrenergic receptors in rats. Rats were given 10 mg of benzoctamine and drops in their blood pressure were approximately 30mm Hg. The researchers further confirmed that serotonin antagonism was not sufficient to reduce blood pressure by using the highly selective serotonin antagonist 1-(1-naphthyl)piperazine, which was not able to decrease the blood pressure of the rats. These studies have yet to be repeated in humans.
=== Russia and Ukraine === From 2013 to 2022 Galloway was a presenter on the Russian state-controlled television network RT. Galloway called the 2014 Ukrainian Revolution a Western-backed "coup" and a "foreign financed invasion of the sovereignty of Ukraine". He believes Russia's annexation of Crimea was legitimate, because he said the disputed 2014 Crimean status referendum showed that "the huge majority of people in Crimea wanted to leave Ukraine". In a 2016 interview of Nigel Farage, Galloway said "I respect Putin and I think he's very popular in Russia". When Russian opposition leader Alexei Navalny was poisoned in August 2020, Galloway claimed on RT that Navalny was a white supremacist. In early 2022, Galloway dismissed claims that Russia was about to invade Ukraine, writing "I told you it wasn't. You were wrong. I was right". When Russia invaded Ukraine ten days later, he said the invasion was "not what I wanted", but he blamed the invasion on "the West" and accused it of "Pumping Ukraine full of NATO weapons, mercenaries and propaganda". He suggested that the Bucha massacre was staged. Galloway was accused of being an apologist and propagandist for Russian president Vladimir Putin by the larger political parties. Jamie Blackett ended their political alliance All for Unity over their disagreement on Ukraine. The Scottish Liberal Democrats leader, Alex Cole-Hamilton, called Galloway "an apologist for Russian expansionist aggression" and said that Galloway's "association with RT has lent legitimacy and influence to the propaganda apparatus of a hostile power".
A juice bar is an establishment that primarily serves prepared juice beverages such as freshly squeezed or extracted fruit juices, juice blends, fruit smoothies (a thick fruit drink, often iced), or other juices such as fresh wheatgrass juice. Sometimes other solid ingredients or nutritional supplements may be added as boosters, such as fresh bananas, nuts or nut butter, bodybuilding supplements, soy protein powder, or others such as whey or hemp protein powders, wheat germ, spirulina, or chlorella. Also, if less juice is used with these same ingredients, drinks called health shakes may be produced. Juice bars share some of the characteristics of a coffeehouse, a soda fountain, a café, and a snack bar, such as providing blended drinks and food, such as sandwiches. Juice bars may be standalone businesses in cities or located at gyms, along commuter areas, near lunchtime areas, at beaches, or at tourist attractions. In Mexico, juice bars have become more popular in the 2000s. Mexican juice bars often also sell healthy beverages and snacks.
By 25 September, an army of around 40,000 Iraqi, Syrian, and Houthi militants were concentrated around the Golan Heights, which the Institute for the Study of War argued was to defend against an Israeli invasion of Lebanon. The number of displaced Lebanese people reached an estimated 500,000. On 26 September, an Israeli strike on a three-story building in Younine killed at least 19 Syrians and a Lebanese person, mostly women or children, and injured eight others. On 27 September, Israel struck Hezbollah's central headquarters in Beirut, targeting Hezbollah leader Hassan Nasrallah. Al-Manar reported that four buildings collapsed in the attack. At least five other people died, including Ali Karaki, Hezbollah's commander of the southern front since 1982, and at least 100 were injured. On 28 September, the Lebanese National News Agency reported that IDF strikes struck civil defense centres and a medical clinic in Taybeh and Deir Siriane killing 11 medical staff and injuring 10 others. On 29 September, an Israeli air strike on a home in Dahr-al-Ain killed at least 11 people. The Lebanese National News Agency reported that at least 17 members of a family were killed and several others were trapped under rubble in an Israeli air strike in Zboud. An Israeli strike in Ain El Delb killed 45 people and injured at least 75 others. An Israeli strike in Bekaa killed 12 people and injured 20 others. On 30 September, Israel informed the United States that it intended to carry out a ground maneuver in Lebanon aimed at clearing Hezbollah's infrastructure along the border.
Sources: en.wikipedia.org
Structural variations, such as deletions, duplications, inversions, translocations, and other rearrangements, are common in human genomes. These variations can have significant impacts on genome functions, and have been implicated in many diseases. Linked-read sequencing technology labels all reads that originate from the same long DNA fragment with the same barcode, so it enables the detection of a large number of structural variants. Complexity of structural variants can be resolved with linked-read sequencing, and provide a complete picture of the genomic landscape. Many scientists have already been using linked-read sequencing to identify and characterise structural variants in diverse populations, including people with genetic disorders or cancers
SSEP can be used to locate lesions such as peripheral nerve or spinal cord. VEP and BAEP can supplement neuroimaging as part of workups to diagnose diseases such as multiple sclerosis. Short latency EPs such as SSEP, VEP, and BAEP can be used to indicate prognosis for traumatic and anoxic brain injury. Early after anoxic brain injury, no response indicates mortality accurately. In traumatic brain injury, abnormal responses indicates failure to recover from coma. In both types of injury, normal responses may indicate good outcome. Moreover, recovery in responses often indicates clinical recovery. Long and Allen were the first investigators to report the abnormal brainstem auditory evoked potentials (BAEPs) in an alcoholic woman who recovered from acquired central hypoventilation syndrome. These investigators hypothesized that their patient's brainstem was poisoned, but not destroyed, by her chronic alcoholism.
A packaging gas is used to pack sensitive materials such as food into a modified atmosphere environment. The gas used is usually inert, or of a nature that protects the integrity of the packaged goods, inhibiting unwanted chemical reactions such as food spoilage or oxidation. Some may also serve as a propellant for aerosol sprays like cans of whipped cream. For packaging food, the use of various gases is approved by regulatory organisations. In the food sector (modified atmosphere packaging, MAP), the gas composition—typically N₂/CO₂ and, depending on the product, O₂—is selected to manage respiration and microbial growth; the atmosphere is applied by flushing the pack or by in-line injection. FAO guidance describes principles and uses, while manufacturer application notes provide examples of common gases and supply arrangements used in industry. Their E numbers are included in the following lists in parentheses. These gas types do not cause a chemical change to the substance that they protect.
Sources: en.wikipedia.org
Dapagliflozin/saxagliptin, sold under the brand name Qtern, is a fixed-dose combination anti-diabetic medication used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. It is a combination of dapagliflozin and saxagliptin. It is taken by mouth. The most common side effects include upper respiratory tract infection (such as nose and throat infections) and, when used with a sulphonylurea, hypoglycaemia (low blood glucose levels). Dapagliflozin/saxagliptin was approved for medical use in the European Union in July 2016, and in the United States in February 2017.
== Impact on protein function == Missense mutation refers to a change in one amino acid in a protein arising from a point mutation in a single nucleotide. Amino acids are the building blocks of proteins. Missense mutations are a type of nonsynonymous substitution in a DNA sequence. Two other types of nonsynonymous substitutions are nonsense mutations, in which a codon is changed to a premature stop codon that results in the resulting protein being cut short, and nonstop mutations, in which a stop codon deletion results in a longer but nonfunctional protein. The latter two types are not considered to be missense mutations.
Le Havre Octeville Airport which is located 5 km (3 mi) north of Le Havre at the town of Octeville-sur-Mer and managed by CODAH. The airport does not have any scheduled services to or from Le Havre at this time. Currently, air travel is served by the nearest Caen–Carpiquet Airport which is located approximately 54 km away from Le Havre. The main destination is the Transport hub of Lyon. Many holiday destinations are offered each year (Tunisia, Balearic Islands, Portugal, Greece, Bulgaria, etc.) through local travel agencies that charter aircraft. There is also the Flying club Jean Maridor at the airport. The Channel maritime links with Portsmouth in southern England with P&O Ferries ended on 30 September 2005 to be taken over by LD Lines who had changed the configuration. Two services to Portsmouth are provided daily from the Terminal de la Citadelle until ceasing operations in 2014, the route has since been taken over by Brittany Ferries. It will cease in September 2026. The link to Ireland was moved to the port of Cherbourg. Crossing times to Portsmouth vary from five hours and thirty minutes to eight hours. Popular alternative routes going to areas close to Le Havre include Newhaven to Dieppe, and Poole to Cherbourg.
== Contributions == De made significant contributions to the recent understanding of cholera and related diarrhoeal diseases and set a permanent milestone in the modern view of diseases caused by bacterial exotoxins. Followed by the discovery of Vibrio cholerae in 1884 by Robert Koch, many works have been carried out all over the world to answer many questions related with its pathogenesis and mode of transmission in causing outbreaks. The seminal works of De in Calcutta (now Kolkata) during 1950–60 breached several qualms pertaining to the enteric toxin produced by bacteria including V. cholerae and Escherichia coli. Three of his works viz., ligated intestinal loop method (which was a reinvention of Violle and Crendiropoulo method in 1915, but De was unaware of this work and made an independent discovery) for studying cholera in rabbit model; ileal loop model to demonstrate the association of some strains of E. coli with diarrhoea and lastly but most importantly is his discovery of cholera toxin in 1959 in the cell-free culture filtrate of V. cholerae that stimulated a specific cellular response. As noted by Garfield in his 1986 tribute, De was the first to demonstrate that cholera bacteria secrete enterotoxin. This discovery eventually promoted research to find a treatment aimed directly at neutralising the cholera enterotoxin. De's paper "Enterotoxicity of bacteria-free culture-filtrate of Vibrio cholerae," while initially unrecognised, today is considered a milestone in the history of cholera research. Biochemist W. E.
Sources: en.wikipedia.org
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.
A fatty diacid side chain promotes reversible binding to serum albumin. This association slows renal clearance and protects the peptide from rapid enzymatic degradation. The result is a prolonged circulation time that supports weekly administration.
The first regulatory approval, for type 2 diabetes, was granted in the United States in 2022. An additional approval for chronic weight management followed in 2023. Availability and approved indications vary by country and are set by each national regulator.
It is a synthetic peptide of 39 amino acids bearing a lipid side chain. Its size and architecture place it outside the small-molecule class, and laboratories generally handle it with the precautions used for biologic-like molecules.